Lindsay E Nyhoff
Overview
Explore the profile of Lindsay E Nyhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joshi D, Nyhoff L, Zarnitsyna V, Moreno A, Manning K, Linderman S, et al.
iScience
. 2023 Oct;
26(10):107967.
PMID: 37822504
As SARS-CoV-2 becomes endemic, it is critical to understand immunity following early-life infection. We evaluated humoral responses to SARS-CoV-2 in 23 infants/young children. Antibody responses to SARS-CoV-2 spike antigens peaked...
2.
Wimmers F, Burrell A, Feng Y, Zheng H, Arunachalam P, Hu M, et al.
Cell
. 2023 Sep;
186(21):4632-4651.e23.
PMID: 37776858
The dynamics of immunity to infection in infants remain obscure. Here, we used a multi-omics approach to perform a longitudinal analysis of immunity to severe acute respiratory syndrome coronavirus 2...
3.
Joshi D, Nyhoff L, Zarnitsyna V, Moreno A, Manning K, Linderman S, et al.
medRxiv
. 2023 Apr;
PMID: 37090559
Since the emergence of SARS-CoV-2, research has shown that adult patients mount broad and durable immune responses to infection. However, response to infection remains poorly studied in infants/young children. In...
4.
Valanparambil R, Carlisle J, Linderman S, Akthar A, Millett R, Lai L, et al.
J Clin Oncol
. 2022 Jun;
40(33):3808-3816.
PMID: 35759727
Purpose: To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after...
5.
Mantus G, Nyhoff L, Edara V, Zarnitsyna V, Ciric C, Flowers M, et al.
Cell Rep Med
. 2022 Apr;
3(4):100603.
PMID: 35480625
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic highlights the importance of determining the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination. Herein, we characterize the...
6.
Bonami R, Thurman C, Verma S, Westlake C, Nyhoff L, Barron B, et al.
Front Immunol
. 2022 Apr;
13:748284.
PMID: 35422819
Bruton's tyrosine kinase () deficiency preferentially eliminates autoreactive B cells while sparing normal humoral responses, but has not been studied in mucosal immunity. Commensal microbes and intact BTK signaling have...
7.
Edara V, Manning K, Ellis M, Lai L, Moore K, Foster S, et al.
Cell Rep Med
. 2022 Mar;
3(2):100529.
PMID: 35233550
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure...
8.
Edara V, Manning K, Ellis M, Lai L, Moore K, Foster S, et al.
bioRxiv
. 2022 Jan;
PMID: 34981056
The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the...
9.
Nyhoff L, Griffith A, Clark E, Thomas J, Khan W, Kendall P
J Immunol
. 2021 Nov;
207(12):2922-2932.
PMID: 34799428
Bruton's tyrosine kinase (Btk) propagates B cell signaling, and BTK inhibitors are in clinical trials for autoimmune disease. Although autoreactive B cells fail to develop in the absence of Btk,...
10.
Cohen K, Linderman S, Moodie Z, Czartoski J, Lai L, Mantus G, et al.
Cell Rep Med
. 2021 Jul;
2(7):100354.
PMID: 34250512
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding...